News

Under the strategic agreement, the companies expect to launch two products in the first half of 2008. IntelGenx will complete the development of the products, using its patented

The Personal Diabetes Manager (PDM) with integrated DexCom technology is expected to broaden Insulet’s portfolio of diabetes management products. The development agreement between Insulet and DexCom also contemplates

The trial will be conducted at a single site in Hawaii, which the company currently expects to start in April 2008, pending successful completion of financing sufficient funding

The primary endpoint of the open-label, randomized, crossover study was to evaluate the effects of morning dosing of Zegerid capsules, Protonix tablets and Prevacid capsules on 24-hour gastric

Through the definitive license agreement Taisho will grant exclusive development and commercialization rights outside Japan for TS-032 to Pfizer. Under the agreement, Taisho will receive from Pfizer an

The Spinal Cord Injury Project is the first focus of the W M Keck Center for Collaborative Neuroscience at Rutgers University. The study, combined with BrainStorm’s unique differentiation

The notes will be convertible, in certain circumstances, into common stock of OSI based upon a base conversion rate, which, under certain circumstances will be increased pursuant to

This study was a multi-center, double-blind, parallel-group, randomized, placebo-controlled trial in 381 adults ages 21 to 64 with co-morbid chronic insomnia and GAD. The study evaluated the overall

The four-year grant, which is part of the Foundation’s LEAPS (Linked Efforts to Accelerate Parkinson’s Solutions) initiative, was awarded to Alnylam, Mayo Clinic of Jacksonville, Florida, and the